Romidepsin, an HDAC1/2 selective inhibitor, is able to inhibit ovarian cancer metastasis through inhibiting the functions of CHD4 that are mediated by histone deacetylase [91]. This evidence concerns the gene CHD4 and ovarian carcinoma.